Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + etoposide + rituximab

Development stage: Unknown
Lead developer: Takeda
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline), etoposide (a topoisomerase II inhibitor), and rituximab (an anti-CD20 monoclonal antibody). This regimen is primarily used for treating B-cell malignancies including non-Hodgkin lymphoma and chronic lymphocytic leukemia. The cytotoxic agents work through different mechanisms to prevent DNA replication and cell division, while rituximab specifically targets CD20-positive B cells, enhancing the efficacy of the chemotherapy components.

Targets

CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + etoposide + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + etoposide + rituximab.

Explore the full profile